effici
individu
age
provid
lifelong
protect
singl
administr
evok
advers
reaction
stabl
variou
condit
temperatur
light
transport
easi
administ
prefer
oral
avail
unlimit
quantiti
cheap
figur
characterist
hypothet
ideal
vaccin
sinc
vaccin
document
edward
jenner
becom
success
mean
prevent
infecti
diseas
save
million
live
everi
year
howev
applic
vaccin
current
limit
prevent
infecti
diseas
vaccin
pipelin
includ
antidrug
abus
vaccin
nicotin
cocain
vaccin
allergi
cancer
alzheim
diseas
modern
biotechnolog
enorm
impact
current
vaccin
develop
elucid
molecular
structur
pathogen
tremend
progress
made
immunolog
well
develop
proteom
bioinformat
led
identifi
cation
protect
antigen
way
deliv
togeth
technolog
advanc
caus
move
empir
vaccin
develop
ration
approach
major
goal
modern
vaccin
technolog
fulfi
requir
ideal
vaccin
summar
fig
express
antigen
epitop
smallest
molecular
structur
recogn
immun
system
andor
isol
antigen
confer
effect
immun
respons
elimin
structur
caus
deleteri
effect
thu
betterdefi
ned
product
obtain
result
improv
safeti
addit
modern
methodolog
may
provid
simpler
product
process
select
vaccin
compon
follow
section
immunolog
principl
import
vaccin
design
summar
subsequ
classic
vaccin
result
modern
genet
chemic
engin
technolog
address
classic
modern
vaccin
list
tabl
current
strategi
use
develop
manufactur
new
vaccin
discuss
section
modern
vaccin
technolog
intent
provid
comprehens
review
rather
explain
modern
approach
vaccin
develop
illustr
approach
repres
exampl
last
section
pharmaceut
aspect
vaccin
dealt
natur
infect
human
immun
system
case
launch
immunolog
respons
particular
pathogen
recoveri
diseas
immunolog
respons
inde
protect
affect
individu
diseas
ideal
case
forev
phenomenon
call
specifi
c
immun
caus
presenc
circul
antibodi
cytotox
cell
memori
cell
memori
cell
becom
activ
type
antigen
materi
enter
bodi
later
occas
unlik
primari
respons
fi
rst
infect
respons
repeat
infect
fast
usual
suffi
cientli
strong
prevent
reoccurr
diseas
principl
vaccin
mimick
infect
way
natur
specifi
c
defens
mechan
host
pathogen
activ
host
remain
free
diseas
normal
result
natur
infect
effectu
administr
antigen
compon
consist
deriv
relat
pathogen
success
vaccin
reli
induct
protect
immun
respons
longlast
immunolog
memori
vaccin
also
refer
activ
immun
host
immun
system
activ
respond
infect
humor
cellular
immun
respons
result
adapt
immun
particular
pathogen
immun
respons
gener
highli
specifi
c
discrimin
pathogen
speci
often
also
differ
strain
within
one
speci
eg
strain
meningococci
polioviru
infl
uenza
viru
albeit
sometim
hurdl
vaccin
develop
high
specifi
citi
immun
system
allow
almost
perfect
balanc
respons
foreign
antigen
toler
respect
selfantigen
apart
activ
immun
administr
specifi
c
antibodi
util
shortliv
immunolog
protect
host
term
passiv
immun
fig
tradit
activ
immun
mainli
serv
prevent
infecti
diseas
wherea
passiv
immun
appli
prevent
therapi
infecti
diseas
recent
develop
new
potenti
applic
vaccin
activ
immun
emerg
prevent
diseas
infecti
diseas
eg
cancer
treatment
substanc
abus
eg
nicotin
addict
vaccin
refer
therapeut
vaccin
differ
passiv
activ
immun
outlin
fig
sinc
antibodi
prepar
passiv
immun
fall
strict
defi
nition
vaccin
discuss
gener
immun
reaction
pathogen
vaccin
follow
sever
distinct
step
ultim
lead
longlast
protect
pathogen
memori
cell
step
uptak
vaccin
consist
either
entir
pathogen
antigen
compon
thereof
phagocyt
cell
activ
migrat
profession
antigenpres
cell
apc
infect
tissu
peripher
lymphoid
organ
antigen
present
lymphocyt
fi
nalli
activ
inhibit
b
lymphocyt
entir
process
illustr
fig
describ
success
step
lead
immun
respons
pathogen
import
design
vaccin
pathogen
everi
immun
reaction
pathogen
start
activ
innat
immun
system
nonspecifi
c
fast
respons
antigen
import
constitu
innat
system
antigen
sampl
overview
step
lead
immun
administr
vaccin
upon
subcutan
intramuscular
administr
vaccin
compon
taken
phagocyt
cell
macrophag
dendrit
cell
dc
resid
peripher
tissu
express
pattern
recognit
receptor
prr
recogn
pathogenassoci
molecular
pattern
pamp
profession
antigenpres
cell
apc
taken
antigen
becom
activ
start
migrat
toward
nearbi
lymph
node
insid
lymph
node
antigen
process
apc
present
lymphocyt
recogn
antigen
receiv
appropri
costimulatori
signal
becom
activ
antigenspecifi
c
b
lymphocyt
clonal
expand
produc
multipl
progenitor
recogn
antigen
addit
memori
b
cell
form
provid
longterm
sometim
lifelong
protect
infect
pathogen
cell
like
macrophag
dendrit
cell
dc
innat
respons
lead
immunolog
memori
phagocyt
cell
sens
conserv
microbi
structur
call
pathogenassoci
molecular
pattern
pamp
via
pattern
recognit
receptor
prr
cell
surfac
bacteri
pamp
cytoplasm
viral
pamp
exampl
prr
tolllik
receptor
tlr
scaveng
receptor
ctype
lectin
tabl
tlr
consist
famili
receptor
member
recogn
differ
pattern
pathogen
kawai
akira
tlr
found
mani
cell
includ
macrophag
dc
dc
also
engulf
materi
extracellular
environ
receptorindepend
process
call
pinocytosi
besid
mediat
uptak
antigen
materi
surround
tissu
prr
also
play
import
role
trigger
cytokin
network
eventu
infl
uenc
type
adapt
immun
respons
evok
pathogen
phagocyt
cell
taken
pathogen
infect
tissu
becom
activ
start
produc
proinfl
ammatori
cytokin
tumor
necrosi
well
chemokin
chemokin
recruit
phagocyt
cell
neutrophil
monocyt
infect
site
wherea
proinfl
ammatori
cytokin
induc
fever
product
acutephas
respons
protein
opson
pathogen
phagocyt
cell
includ
dc
macrophag
also
b
cell
serv
apc
present
process
antigen
determin
lymphocyt
peripher
lymphoid
organ
instanc
dc
taken
antigen
infect
tissu
becom
activ
migrat
via
affer
lymphat
vessel
toward
nearbi
lymph
node
encount
pathogenspecifi
c
lymphocyt
take
place
peripher
lymphoid
organ
primari
meet
place
cell
innat
immun
system
apc
cell
adapt
immun
system
cell
b
cell
upon
interact
apc
pathogenspecifi
c
cell
b
cell
activ
provid
acquir
appropri
signal
apc
besid
antigenspecifi
c
bind
via
antigen
receptor
lymphocyt
requir
costimulatori
signal
via
interact
accessori
costimulatori
molecul
lymphocyt
apc
cellcel
interact
essenti
proper
stimul
lymphocyt
without
accessori
signal
antigenspecifi
c
cell
may
becom
anerg
lymphocyt
receiv
appropri
signal
activ
clonal
expand
gener
multipl
progenitor
recogn
antigen
clonal
expans
typic
featur
adapt
immun
system
discuss
detail
adapt
immun
system
involv
elimin
pathogen
late
phase
infect
gener
immunolog
memori
compris
b
lymphocyt
bear
antigenspecifi
c
receptor
adapt
immun
system
divid
humor
immun
cellmedi
immun
cmi
see
fig
tabl
humor
respons
result
antibodi
format
contain
cellmedi
event
see
fig
panel
b
cmi
result
gener
cytotox
cell
see
fig
panel
c
action
antibodi
cell
depend
accessori
factor
mention
tabl
gener
infect
pathogen
protect
vaccin
humor
cellular
respons
gener
indic
need
effi
cient
protect
balanc
humor
cellular
respons
howev
differ
wide
pathogen
depend
pathogen
present
adapt
immun
system
apc
may
consequ
design
particular
vaccin
see
vaccin
design
relat
immun
respons
antibodi
typic
repres
humor
immun
antibodi
belong
one
four
differ
immunoglobulin
class
igm
igg
iga
ige
cf
chap
upon
immun
b
cell
express
specifi
c
antibodi
cell
surfac
repres
fi
fth
immunoglobulin
class
igd
bind
intact
antigen
activ
surfacebound
antibodi
bind
specifi
c
epitop
pathogen
close
cooper
thelper
cell
h
cell
b
cell
becom
activ
eventu
result
massiv
clonal
prolifer
prolifer
b
cell
call
plasma
cell
excret
larg
amount
solubl
antibodi
fig
panel
b
antibodi
abl
prevent
infect
diseas
sever
mechan
bind
antibodi
cover
antigen
fc
constant
fragment
rear
end
immunoglobulin
phagocyt
cell
like
macrophag
express
surfac
receptor
fc
allow
target
opson
antibodyco
antigen
cell
follow
enhanc
phagocytosi
immun
complex
ie
antibodi
bound
target
antigen
activ
complement
system
protein
becom
cytolyt
bacteria
envelop
virus
infect
cell
phagocyt
cell
may
express
receptor
complement
factor
associ
immun
complex
bind
activ
complement
factor
enhanc
phagocytosi
virus
neutral
antibodi
bind
near
receptor
bind
site
viru
surfac
may
prevent
bind
entri
host
cell
antibodi
effect
certain
infecti
microorgan
may
limit
valu
cmi
major
protect
mechan
cell
type
known
exhibit
cytotox
two
antigen
sensit
specifi
citi
special
import
respect
vaccin
design
cytotox
lymphocyt
ctl
react
target
cell
kill
releas
cytolyt
protein
like
perforin
target
cell
express
nonself
antigen
like
viral
protein
tumor
antigen
identifi
ed
ctl
respons
antibodi
respons
highli
specifi
c
cell
involv
delayedtyp
hypersensit
dth
abl
kill
target
cell
ctl
also
helper
type
see
function
enabl
activ
macrophag
besid
plasma
cell
cytotox
cell
mani
case
memori
b
cell
develop
memori
b
cell
produc
solubl
antibodi
repeat
antigen
contact
respons
time
develop
antibodyexcret
plasma
cell
shorter
compar
b
cell
occurr
differ
type
immun
respons
vaccin
result
differ
antigen
process
vaccin
apc
result
activ
h
cell
fig
major
histocompat
complex
mhc
molecul
play
import
role
present
process
antigen
cell
cell
expos
mhc
class
molecul
also
mhc
class
ii
molecul
surfac
apc
carri
class
ii
molecul
process
solubl
exogen
extracellular
protein
complic
structur
microorgan
see
fig
panel
endocytosi
protein
subject
limit
proteolysi
return
peptid
surfac
apc
combin
class
ii
molecul
present
tcell
receptor
h
cell
h
cell
provid
type
help
necessari
effector
function
b
cell
type
help
character
lymphokin
pattern
produc
interleukin
lymphokin
trigger
b
cell
eventu
result
product
igm
igg
antibodi
cell
carri
mhc
class
molecul
process
endogen
intracellularli
produc
antigen
like
viral
tumor
antigen
present
combin
class
molecul
cell
surfac
see
fig
panel
c
class
iantigen
combin
apc
recogn
tcell
receptor
ctl
thcell
provid
help
ctl
induct
cmi
fig
panel
c
type
help
need
product
tumor
necrosi
factor
thcell
posit
regardless
whether
function
increas
evid
balanc
import
immunolog
paramet
sinc
diseas
coincid
autoimmun
allergi
type
respons
thelper
cell
phenotyp
identifi
ed
play
role
autoimmun
diseas
eg
cell
suppress
immun
respons
eg
reg
cell
ration
design
new
vaccin
understand
mechan
protect
immun
pathogen
vaccin
develop
crucial
instanc
prevent
tetanu
high
blood
titer
antibodi
tetanu
toxin
requir
mycobacteri
diseas
tuberculosi
macrophageactiv
cmi
effect
case
infl
uenza
viru
infect
ctl
probabl
play
signifi
cant
role
besid
antibodi
importantli
immun
effector
mechan
trigger
vaccin
henc
success
immun
depend
natur
protect
compon
also
present
form
presenc
adjuv
rout
administr
present
form
vaccin
one
determin
infl
uenc
extent
type
immun
respons
evok
pashin
et
al
pulendran
ahm
dc
apc
play
pivot
role
antigen
determin
vaccin
process
present
cell
peripher
lymphoid
organ
variou
prr
dc
less
abl
sens
type
pathogen
encount
determin
set
costimulatori
signal
proinfl
ammatori
cytokin
gener
apc
present
antigen
thcell
peripher
lymphoid
organ
instanc
pathogen
vaccin
contain
lipoprotein
peptidoglycan
trigger
dc
via
predominantli
gener
respons
wherea
stimul
dc
known
yield
robust
respons
therefor
vaccin
formul
way
appropri
h
respons
trigger
done
present
antigen
nativ
format
case
classic
vaccin
ad
adjuv
stimul
desir
respons
see
respons
b
cell
depend
upon
natur
antigen
two
type
antigen
distinguish
thymusindepend
antigen
includ
certain
linear
antigen
readili
degrad
bodi
repeat
determin
bacteri
polysaccharid
abl
stimul
b
cell
without
h
cell
involv
thymusindepend
antigen
induc
immunolog
memori
thymusdepend
antigen
provok
littl
antibodi
respons
tcelldeplet
anim
protein
typic
repres
thymusdepend
antigen
prerequisit
thymu
depend
physic
linkag
exist
site
recogn
b
cell
h
cell
thymusindepend
antigen
coupl
carrier
protein
contain
h
epitop
becom
thymu
depend
result
conjug
abl
induc
memori
antigen
protein
epitop
continu
discontinu
continu
epitop
involv
linear
peptid
sequenc
usual
consist
ten
amino
acid
residu
protein
see
fig
panel
discontinu
epitop
compris
amino
acid
residu
sometim
far
apart
primari
sequenc
brought
togeth
uniqu
fold
protein
see
fig
panel
b
antibodi
recognit
bcell
epitop
whether
continu
discontinu
usual
depend
conform
threedimension
structur
tcell
epitop
hand
continu
peptid
sequenc
conform
seem
play
role
tcell
recognit
immunolog
respons
vaccin
depend
rout
administr
current
vaccin
administ
intramuscularli
subcutan
parenter
immun
usual
induc
system
immun
howev
mucos
eg
oral
intranas
intravagin
immun
may
prefer
may
induc
mucos
system
immun
mucos
surfac
common
entranc
mani
pathogen
induct
mucos
secretori
iga
respons
may
prevent
attach
entri
pathogen
host
exampl
antibodi
cholera
need
gut
lumen
inhibit
adher
colon
intestin
wall
also
oral
administ
salmonella
typhi
invad
mucos
line
gut
also
infect
cell
phagocyt
system
throughout
bodi
therebi
stimul
product
secretori
system
antibodi
well
cmi
addit
advantag
mucos
immun
eas
administr
avoid
system
side
effect
holmgren
czerkinski
czerkinski
holmgren
howev
success
mucos
immun
achiev
limit
number
oral
vaccin
eg
oral
polio
cholera
typhoid
fever
rotaviru
vaccin
nasal
infl
uenza
vaccin
flumist
vaccin
base
attenu
see
later
version
pathogen
rout
administr
natur
rout
infect
apart
mucos
rout
research
group
work
needlefre
jet
inject
powder
fl
uid
dermal
deliveri
microneedl
kersten
hirschberg
bal
et
al
see
chap
prerequisit
approach
must
painless
case
sever
immun
given
monoval
vaccin
replac
one
multival
vaccin
product
yet
regist
classic
vaccin
origin
virus
bacteria
divid
live
attenu
vaccin
nonliv
vaccin
addit
three
vaccin
gener
distinguish
nonliv
vaccin
firstgener
vaccin
consist
inactiv
suspens
pathogen
microorgan
littl
purifi
cation
appli
secondgener
vaccin
purifi
cation
step
appli
vari
purifi
cation
pathogen
microorgan
eg
improv
nonliv
polio
vaccin
complet
purifi
cation
protect
compon
eg
polysaccharid
vaccin
thirdgener
vaccin
either
welldefi
ned
combin
protect
compon
eg
acellular
pertussi
vaccin
protect
compon
desir
immunolog
properti
eg
polysaccharid
conjug
carrier
protein
overview
classic
vaccin
gener
given
tabl
introduct
recombin
dna
rdna
technolog
fi
rst
step
improv
live
vaccin
attenu
virul
microorgan
serial
passag
select
mutant
strain
reduc
virul
toxic
exampl
vaccin
strain
oral
polio
vaccin
measlesmumpsrubella
mmr
combin
vaccin
tuberculosi
vaccin
consist
bacil
bcg
altern
approach
chemic
mutagenesi
instanc
treat
salmonella
typhi
nitrosoguanidin
mutant
strain
lack
enzym
respons
virul
isol
germani
fuer
live
attenu
organ
number
advantag
vaccin
nonliv
vaccin
administr
live
vaccin
may
replic
host
figur
two
approach
design
synthet
peptid
vaccin
panel
identifi
cation
sequenc
continu
epitop
immunogen
protein
follow
synthesi
peptid
amino
acid
sequenc
correspond
epitop
panel
b
synthesi
peptid
mimick
discontinu
epitop
determin
threedimension
structur
immunogen
protein
peptid
strongli
bind
protect
antibodi
recogn
discontinu
epitop
select
peptid
mimotop
necessarili
contain
exact
amino
acid
sequenc
constitu
fragment
form
epitop
similar
pathogen
counterpart
confront
host
larger
sustain
dose
antigen
mean
low
dose
requir
gener
vaccin
give
longlast
humor
cellmedi
immun
live
vaccin
also
drawback
live
viral
vaccin
bear
risk
nucleic
acid
sequenc
incorpor
host
genom
moreov
revers
virul
form
may
occur
although
unlik
attenu
seed
strain
contain
sever
mutat
nevertheless
diseas
viral
hepat
aid
cancer
drawback
make
use
classic
live
vaccin
virtual
unthink
furthermor
import
recogn
immun
immunedefi
cient
children
live
organ
lead
seriou
complic
instanc
child
tcell
defi
cienci
may
becom
overwhelm
bcg
die
earli
approach
prepar
vaccin
inactiv
whole
bacteria
virus
number
reagent
eg
formaldehyd
glutaraldehyd
heat
commonli
use
inactiv
exampl
fi
rstgener
approach
pertussi
cholera
typhoid
fever
inactiv
polio
vaccin
nonliv
vaccin
disadvantag
littl
cmi
induc
moreov
frequent
caus
advers
effect
compar
live
attenu
vaccin
secondand
thirdgener
nonliv
vaccin
bacteria
corynebacterium
diphtheria
clostridium
tetani
form
toxin
antibodymedi
immun
toxin
main
protect
mechan
infect
bacteria
toxin
protein
inactiv
formaldehyd
inclus
vaccin
immunogen
toxoid
rel
low
improv
adsorpt
toxoid
suspens
aluminum
salt
combin
antigen
adjuv
still
use
combin
vaccin
rel
frequent
occurr
side
effect
wholecel
pertussi
vaccin
main
reason
develop
subunit
vaccin
develop
thirdgener
acellular
pertussi
vaccin
exemplifi
es
better
insight
factor
import
pathogenesi
immunogen
lead
improv
vaccin
conceiv
subunit
vaccin
consist
limit
number
purifi
ed
immunogen
compon
devoid
toxic
lipopolysaccharid
would
signifi
cantli
reduc
undesir
effect
four
protein
antigen
import
protect
identifi
ed
howev
yet
exist
consensu
optim
composit
acellular
pertussi
vaccin
current
vaccin
contain
differ
amount
two
four
protein
bacteri
capsular
polysaccharid
consist
pathogenspecifi
c
multipl
repeat
carbohydr
epitop
isol
cultur
pathogen
speci
plain
capsular
polysaccharid
secondgener
vaccin
thymusindepend
antigen
poorli
immunogen
infant
show
poor
immunolog
memori
appli
older
children
adult
immunogen
polysaccharid
highli
increas
chemic
coupl
carrier
protein
contain
h
epitop
coupl
make
cell
depend
due
particip
h
cell
activ
respons
carrier
exampl
thirdgener
polysaccharid
conjug
vaccin
includ
meningococc
type
c
pneumococc
haemophilu
infl
uenza
type
b
hib
polysaccharid
vaccin
includ
mani
nation
immun
program
emerg
insight
molecular
pathogenesi
mani
infecti
diseas
make
possibl
attenu
microorgan
effi
cientli
nowaday
make
multipl
delet
risk
revers
virul
state
product
administr
virtual
elimin
prerequisit
attenu
genet
engin
factor
respons
virul
life
cycl
pathogen
known
detail
also
obviou
protect
antigen
must
known
attenu
must
result
reduc
immunogen
exampl
improv
live
vaccin
obtain
homolog
genet
engin
experiment
oral
cholera
vaccin
effect
cholera
vaccin
induc
local
humor
respons
order
prevent
colon
small
intestin
initi
trial
vibrio
cholera
cholera
toxin
ct
mutant
caus
mild
diarrhea
thought
caus
express
accessori
toxin
natur
mutant
isol
neg
toxin
next
ct
detoxifi
ed
rdna
technolog
result
vaccin
strain
call
cvd
well
toler
volunt
suharyono
et
al
tacket
et
al
challeng
experi
adult
volunt
show
protect
garcia
et
al
genet
attenu
live
vaccin
gener
drawback
mention
section
classic
attenu
live
vaccin
reason
surpris
homolog
engin
mainli
restrict
pathogen
use
start
materi
product
subunit
vaccin
see
section
subunit
vaccin
way
improv
safeti
effi
caci
vaccin
use
live
avirul
attenu
organ
carrier
express
protect
antigen
pathogen
bacteria
virus
use
purpos
list
tabl
live
vector
vaccin
creat
recombin
technolog
wherein
one
gene
vector
organ
replac
one
protect
gene
pathogen
administr
live
vector
vaccin
result
effi
cient
prolong
express
antigen
gene
either
vaccin
individu
cell
vector
organ
eg
case
bacteria
carrier
experi
acquir
vaccinia
viru
use
principl
schemat
shown
fig
advantag
vaccinia
viru
vector
includ
proven
safeti
human
smallpox
vaccin
ii
possibl
multipl
immunogen
express
iii
eas
product
iv
rel
heat
resist
v
variou
possibl
administr
rout
multitud
live
recombin
vaccinia
vaccin
viral
tumor
antigen
construct
sever
test
clinic
jaoko
et
al
jacob
et
al
demonstr
product
gene
code
viral
envelop
protein
correctli
process
insert
plasma
membran
infect
cell
problem
relat
side
effect
immunogen
vaccinia
viru
may
circumv
use
attenu
strain
poxvirus
nonhuman
natur
host
adenovirus
also
use
vaccin
vector
see
also
chap
adenovirus
sever
characterist
make
suitabl
vaccin
vector
infect
broad
rang
divid
nondivid
mammalian
cell
ii
transgen
express
gener
high
increas
use
heterolog
promot
sequenc
iii
adenoviru
vector
mostli
replic
defi
cient
integr
genom
chromosom
host
cell
make
vector
safe
use
iv
upon
parenter
administr
adenoviru
vector
induc
strong
immun
evok
humor
cellular
respons
express
antigen
number
clinic
trial
human
adenoviru
vector
express
antigen
ebola
viru
human
immunodefi
cienci
viru
hiv
sever
acut
respiratori
syndrom
sar
vaccin
diseas
current
progress
termin
nayak
herzog
doubleblind
phase
ii
clinic
trial
studi
effect
vaccin
infect
seroneg
volunt
either
given
vaccin
placebo
strikingli
seem
increas
infect
rate
group
receiv
vaccin
buchbind
et
al
major
limit
use
live
vector
vaccin
preval
preexist
immun
vector
could
neutral
vaccin
immun
system
prime
preexist
immun
describ
adenovir
vector
preval
neutral
antibodi
high
total
popul
use
strain
low
preval
preexist
immun
live
vector
therefor
recommend
nayak
herzog
ahi
et
al
improv
yield
facilit
product
andor
improv
safeti
proteinbas
vaccin
protein
antigen
nowaday
often
produc
recombinantli
ie
express
host
cell
safe
handl
allow
high
express
level
heterolog
host
use
express
immunogen
protein
includ
yeast
bacteria
insect
cell
plant
cell
mammalian
cell
line
hepat
b
surfac
antigen
hbsag
previous
obtain
plasma
infect
individu
express
baker
yeast
saccharomyc
cerevisia
valenzuela
et
al
vanlandschoot
et
al
mammalian
cell
chines
hamster
ovari
cell
burnett
et
al
raz
et
al
transform
host
cell
plasmid
contain
hbsagencod
gene
express
system
yield
hbsag
particl
also
call
viruslik
particl
vlp
structur
ident
nativ
viru
advantag
safeti
consist
qualiti
high
yield
yeastderiv
vaccin
becom
avail
worldwid
appear
safe
effi
caciou
classic
plasmaderiv
vaccin
two
human
papillomaviru
hpv
vaccin
current
market
produc
recombin
protein
like
hbsag
assembl
spontan
viruslik
particl
antigen
gardasil
quadrival
hpv
vaccin
produc
yeast
wherea
antigen
bival
vaccin
cervarix
produc
insect
cell
identifi
cation
protect
epitop
possibl
incorpor
correspond
peptid
sequenc
genet
fusion
carrier
protein
hbsag
hepat
b
core
antigen
franci
larch
peptideencod
dna
sequenc
synthes
insert
carrier
protein
gene
exampl
recombin
peptid
approach
malaria
vaccin
base
repeat
asnalaasnpro
sequenc
plasmodium
falciparum
surfac
antigen
gene
encod
peptid
fuse
hbsag
gene
fusion
product
express
yeast
cell
vreden
et
al
genet
fusion
peptid
protein
offer
possibl
produc
protect
epitop
toxic
antigen
deriv
pathogen
speci
part
nontox
protein
express
harmless
speci
furthermor
uniform
product
obtain
comparison
variabl
chemic
conjug
see
section
synthet
peptidebas
vaccin
principl
vaccin
could
consist
relev
epitop
instead
intact
pathogen
protein
epitop
small
enough
produc
synthet
peptid
peptidebas
vaccin
would
much
better
defi
ned
classic
vaccin
make
concept
peptid
vaccin
attract
howev
turn
diffi
cult
develop
vaccin
today
licens
peptidebas
vaccin
avail
yet
nevertheless
import
progress
made
synthet
peptid
vaccin
enter
clinic
eg
immunotherapi
cancer
melief
van
der
burg
understand
complex
peptid
vaccin
one
distinguish
differ
type
epitop
epitop
recogn
antibodi
b
cell
often
conform
depend
van
regenmortel
reason
diffi
cult
identifi
accur
manipul
antigen
digest
clone
part
gene
often
affect
bcell
epitop
integr
accur
way
identifi
epitop
elucid
crystal
structur
antigenantibodi
complex
diffi
cult
time
consum
although
crystallographi
reveal
molecular
interact
unsurpass
detail
molecular
complex
like
much
dynam
solut
epitop
identifi
ed
synthes
function
peptid
proven
diffi
cult
peptid
need
conform
restrain
achiev
cycliz
peptid
oomen
et
al
use
scaffold
synthes
complex
peptid
structur
timmerman
et
al
regard
conform
tcell
epitop
less
demand
present
natur
process
peptid
apc
cell
result
tcell
epitop
linear
discern
epitop
amino
acid
residu
mhc
class
restrict
epitop
amino
acid
residu
mhc
class
ii
restrict
main
requir
fi
bind
groov
mhc
molecul
high
enough
affi
niti
studi
peptidebas
cancer
vaccin
shown
contain
epitop
order
elicit
protect
immun
respons
furthermor
minim
peptid
extern
load
mhc
molecul
cell
shown
induc
less
robust
respons
longer
peptid
requir
intracellular
process
uptak
dc
anoth
point
consid
variabl
repertoir
mhc
molecul
patient
popul
impli
tcell
epitopebas
peptid
vaccin
contain
sever
tcell
epitop
follow
concept
clinic
trial
overlap
long
peptid
vaccin
shown
promis
result
immunotherapi
patient
hpvinduc
malign
melief
van
der
burg
immun
nucleic
acid
vaccin
involv
administr
genet
materi
plasmid
dna
messeng
rna
encod
desir
antigen
encod
antigen
express
host
cell
immun
respons
express
antigen
rais
donnelli
et
al
plasmid
dna
produc
replic
e
coli
bacteri
cell
purifi
cation
establish
method
eg
densiti
gradient
centrifug
ionexchang
chromatographi
plasmid
dna
administ
anim
human
mostli
via
intramuscular
inject
favor
properti
muscl
cell
dna
express
probabl
due
rel
low
turnov
rate
prevent
plasmid
dna
rapidli
dispers
divid
cell
intracellular
uptak
dna
encod
protein
express
surfac
host
cell
singl
inject
express
last
year
besid
intramuscular
inject
subcutan
intraderm
intranas
administr
also
seem
effect
needleless
inject
skin
dnacoat
gold
nanoparticl
via
gene
gun
report
requir
less
dna
compar
intramuscular
administr
nucleic
acid
vaccin
offer
safeti
subunit
vaccin
advantag
live
recombin
vaccin
induc
strong
ctl
respons
encod
antigen
addit
bacteri
plasmid
also
ideal
activ
innat
immun
express
mani
phagocyt
cell
recogn
unmethyl
bacteri
dna
main
disadvantag
nucleic
acid
immun
poor
immunogen
man
therefor
often
requir
like
subunit
vaccin
adjuv
deliveri
system
boost
immun
respons
dnaencod
antigen
nevertheless
dna
proven
effect
use
combin
protein
antigen
heterolog
dnaprimeproteinboost
strategi
longterm
safeti
nucleic
acid
vaccin
remain
establish
main
pro
con
nucleic
acid
vaccin
list
tabl
advantag
rna
dna
abl
incorpor
host
dna
drawback
rna
howev
less
stabl
dna
nucleic
acid
code
varieti
antigen
shown
induc
protect
longliv
humor
cellular
immun
respons
variou
speci
includ
man
liu
exampl
dna
vaccin
test
clinic
trial
compris
plasmid
encod
antigen
malaria
antigen
nowaday
vaccin
design
base
inform
encod
genom
particular
pathogen
masignani
et
al
rappuoli
covacci
mani
pathogen
entir
genom
sequenc
number
grow
http
cmrtigrorg
genom
sequenc
pathogen
provid
complet
pictur
protein
vaccin
produc
pathogen
given
time
use
comput
algorithm
protein
either
excret
express
surfac
pathogen
thu
like
avail
recognit
host
immun
system
identifi
ed
recombin
product
purifi
cation
vaccin
candid
screen
immunogen
mice
best
candid
select
use
subunit
vaccin
fig
big
advantag
revers
vaccinolog
eas
novel
candid
antigen
select
without
need
cultiv
pathogen
furthermor
compar
genom
differ
strain
pathogen
conserv
antigen
identifi
ed
serv
broad
spectrum
vaccin
give
protect
strain
serotyp
given
pathogen
one
drawback
approach
limit
identif
proteinbas
antigen
revers
vaccinolog
success
use
identifi
novel
antigen
varieti
pathogen
includ
neisseria
meningitidi
bacillu
anthraci
streptococcu
pneumonia
staphylococcu
aureu
chlamydia
pneumonia
mycobacterium
tuberculosi
sett
rappuoli
induct
longterm
immun
respons
format
antinucl
acid
antibodi
possibl
possibl
construct
multipl
epitop
plasmid
concept
restrict
peptid
protein
antigen
eas
largescal
product
poorli
immunogen
man
revers
vaccinolog
involv
analysi
genom
sequenc
pathogen
silico
aim
identifi
potenti
antigen
potenti
antigen
clone
b
produc
recombinantli
c
subsequ
use
immunolog
screen
entir
process
lead
quick
identifi
cation
limit
number
vaccin
candid
give
protect
infect
pathogen
without
need
test
protein
produc
pathogen
e
adapt
scarselli
et
al
classic
vaccin
applic
prophylact
prevent
infecti
diseas
develop
besid
prophylact
applic
vaccin
may
use
treat
alreadi
establish
diseas
infecti
diseas
cancer
drug
addict
although
develop
therapeut
vaccin
still
infanc
exampl
highlight
immunotherapi
cancer
requir
activ
tumorspecifi
c
cell
although
humor
respons
may
case
eg
nonhodgkin
lymphoma
also
effect
besid
synthet
long
peptidebas
approach
alreadi
describ
sever
strategi
boost
tumorspecifi
c
ctl
respons
vaccin
prepar
patient
tumor
mix
irradi
tumor
cell
cell
extract
bacteri
adjuv
bcg
enhanc
immunogen
altern
heat
shock
protein
isol
patient
tumor
contain
associ
tumor
antigen
use
tumorspecifi
c
vaccin
combin
adjuv
heat
shock
protein
potent
stimul
ctl
respons
tumor
cell
demonstr
sever
clinic
trial
liu
et
al
anoth
approach
genet
alter
tumor
cell
order
make
immunogen
transfect
tumor
cell
gene
encod
costimulatori
molecul
result
direct
activ
tumorspecifi
c
ctl
transform
tumor
cell
garnett
et
al
similar
result
achiev
transform
tumor
cell
gene
encod
cytokin
eg
gmcsf
altern
fi
rst
step
immun
respons
optim
vitro
procedur
dendrit
cell
isol
patient
cultur
vitro
presenc
tumor
antigen
antigen
load
cell
subsequ
given
back
patient
licens
therapeut
prostat
cancer
vaccin
base
principl
cheever
higano
potenc
vaccin
limit
month
extens
life
expect
cost
high
almost
per
patient
substanti
room
improv
therapeut
vaccin
also
develop
treatment
drug
abus
addict
nicotin
cocain
methamphetamin
moreno
janda
idea
evok
humor
immun
reaction
drug
molecul
drug
addict
action
within
central
nervou
system
antibodi
rais
drug
molecul
prevent
passag
molecul
bloodbrain
barrier
thu
prevent
addict
effect
mani
abus
drug
small
nonprotein
substanc
gener
elicit
immun
respons
order
activ
host
immun
system
substanc
need
conjug
protein
ovalbumin
diphtheria
toxin
approach
effect
anim
model
late
midstag
clinic
studi
howev
shown
disappoint
result
vaccin
consist
nicotin
conjug
viruslik
particl
fail
phase
studi
nicotineprotein
conjug
vaccin
fail
phase
demonstr
current
lack
tool
predict
least
minim
risk
late
stage
failur
one
biggest
problem
vaccin
develop
inabl
predict
effi
caci
safeti
new
vaccin
method
phase
studi
anim
model
poorli
predict
even
immunolog
paramet
human
like
induct
pathogenneutr
antibodi
respons
fulli
predict
result
vaccin
effi
caci
measur
term
reduct
diseas
sometim
diffi
cult
symptom
diseas
caus
one
pathogen
eg
infl
uenzalik
ill
measur
protect
one
detect
infl
uenza
viru
group
infl
uenzalik
ill
addit
measur
reduct
diseas
group
trial
need
larg
unknown
get
diseas
sometim
ten
thousand
peopl
includ
phase
trial
system
biolog
approach
may
limit
problem
futur
develop
idea
identifi
gene
signatur
correl
protect
immun
respons
done
combin
gene
express
analysi
eg
lymphocyt
blood
function
assay
like
measur
antibodi
cytokin
cellular
respons
bioinformatician
tri
unravel
pathway
network
gene
involv
immun
respons
eventu
may
possibl
assign
activ
limit
number
gene
protect
immun
respons
nakaya
et
al
perhap
gene
signatur
use
futur
clinic
trial
pulendran
et
al
approach
would
allow
reduct
size
clinic
studi
reduc
risk
late
stage
failur
assess
signifi
canc
anim
model
preclin
phase
vaccin
develop
except
synthet
peptid
antigen
compon
vaccin
deriv
microorgan
anim
cell
optim
express
requir
vaccin
compon
microorgan
anim
cell
genet
modifi
ed
anim
cell
use
cultiv
virus
product
subunit
vaccin
compon
advantag
vaccin
compon
releas
cultur
medium
three
stage
discern
manufactur
cellderiv
vaccin
cultiv
upstream
process
purifi
cation
downstream
process
formul
fi
rst
two
stage
reader
refer
chap
wherea
formul
address
follow
section
success
immun
depend
natur
immunogen
compon
also
present
form
therefor
search
effect
accept
adjuv
import
issu
modern
vaccin
develop
guy
adjuv
defi
ned
materi
increas
humor
cellular
immun
respons
antigen
adjuv
stimul
immun
system
sever
mutual
exclus
mechan
guy
depot
effect
lead
slow
antigen
releas
prolong
antigen
present
ii
attract
stimul
apc
local
tissu
damag
bind
prr
present
apc
iii
deliveri
antigen
region
lymph
node
improv
antigen
uptak
transport
present
apc
colloid
aluminum
salt
hydroxid
phosphat
wide
use
mani
classic
vaccin
formul
adjuv
eg
monophosphoryl
lipid
hpv
vaccin
oilinwat
emuls
infl
uenza
vaccin
introduc
recent
experiment
test
use
veterinari
vaccin
tabl
show
list
wellknown
adjuv
sinc
oral
immun
possibl
avail
vaccin
see
section
rout
administr
strategi
mix
individu
vaccin
order
limit
number
inject
common
practic
sinc
mani
decad
current
vaccin
avail
contain
six
nonrel
antigen
diphtheriatetanuspertussishepat
bpoliohaemophilu
infl
uenza
type
b
vaccin
anoth
exampl
measlesmumpsrubella
mmr
vaccin
alon
combin
varicella
vaccin
sometim
vaccin
contain
antigen
sever
subtyp
particular
pathogen
pneumococc
conjug
vaccin
exampl
vaccin
contain
polysaccharid
thirteen
pneumococc
strain
conjug
carrier
protein
improv
immunogen
combin
vaccin
compon
sometim
result
pharmaceut
well
immunolog
problem
instanc
formaldehydecontain
compon
may
chemic
react
compon
unstabl
antigen
may
need
freez
dri
wherea
antigen
frozen
compon
compat
mix
prior
inject
shortterm
incompat
end
dualchamb
syring
develop
immunolog
point
view
immun
schedul
individu
compon
combin
vaccin
match
even
condit
met
compon
pharmaceut
compat
success
combin
vaccin
warrant
vaccin
compon
combin
vaccin
may
exhibit
differ
behavior
vivo
compar
separ
administr
compon
instanc
enhanc
paradiso
et
al
well
suppress
mallet
et
al
humor
immun
respons
report
aluminum
salt
antigen
adsorpt
crucial
secondand
thirdgener
classic
vaccin
modern
vaccin
betterdefi
ned
product
term
immunogen
structur
puriti
mean
product
character
combin
appropri
biochem
physicochem
immunochem
techniqu
see
chap
vaccin
meet
similar
standard
biotechnolog
pharmaceut
use
modern
analyt
techniqu
design
releas
new
vaccin
gain
import
current
anim
experi
need
qualiti
control
mani
vaccin
vitro
analyt
techniqu
may
eventu
partli
substitut
preclin
test
vivo
develop
product
process
vaccin
compon
combin
suitabl
assay
defi
ned
assay
subsequ
appli
routin
product
column
chromatograph
hplc
electrophoret
techniqu
like
gel
electrophoresi
capillari
electrophoresi
provid
inform
puriti
molecular
weight
electr
charg
vaccin
compon
physicochem
assay
compris
mass
spectrometri
spectroscopi
includ
circular
dichroism
fl
uoresc
spectroscopi
inform
obtain
mainli
molecular
weight
conform
vaccin
compon
immunochem
assay
enzymelink
immunoassay
radioimmunoassay
power
method
quantifi
cation
vaccin
compon
use
monoclon
antibodi
prefer
specifi
citi
protect
human
antibodi
inform
obtain
conform
access
epitop
antibodi
direct
moreov
use
biosensor
make
possibl
measur
antigenantibodi
interact
momentarili
allow
accur
determin
bind
kinet
affi
niti
constant
depend
specifi
c
characterist
vaccin
store
solut
freezedri
formul
usual
shelf
life
depend
composit
physicochem
characterist
vaccin
formul
storag
condit
typic
order
sever
year
qualiti
contain
infl
uenc
longterm
stabil
vaccin
eg
adsorpt
ph
chang
result
contact
vial
wall
use
ph
indic
temperatureor
timesensit
label
vial
vaccin
monitor
chang
color
expos
extrem
temperatur
expir
date
avoid
unintent
administr
inappropri
store
expir
vaccin
despit
tremend
success
classic
vaccin
still
mani
infecti
diseas
diseas
eg
cancer
effect
vaccin
exist
although
modern
vaccin
like
biopharmaceut
expens
calcul
may
indic
costeffect
vaccin
mani
diseas
addit
grow
resist
exist
arsen
antibiot
increas
need
develop
vaccin
common
bacteri
infect
expect
novel
vaccin
sever
diseas
becom
avail
case
prefer
type
vaccin
chosen
one
differ
option
describ
chapter
aspect
address
design
vaccin
order
approach
characterist
antibodi
neutral
antigen
cell
discrimin
exogen
extracellular
endogen
intracellular
antigen
eventu
result
differ
respons
categori
classic
vaccin
exist
characterist
mention
two
main
problem
relat
immunogen
peptidebas
vaccin
problem
dealt
mention
least
three
advantag
three
disadvantag
nucleic
acid
vaccin
give
one
advantag
one
disadvantag
rna
vaccin
dna
vaccin
stage
discern
manufactur
cellderiv
vaccin
mention
two
exampl
current
avail
combin
vaccin
pharmaceut
immunolog
condit
fulfi
lled
formul
combin
vaccin
answer
characterist
ideal
vaccin
list
fig
antibodi
abl
neutral
antigen
least
four
mechan
fcmediat
phagocytosi
b
complement
activ
result
cytolyt
activ
c
complementmedi
phagocytosi
competit
bind
site
crucial
biolog
activ
antigen
cell
abl
distinguish
exogen
endogen
antigen
type
selfantigen
mhc
antigen
associ
process
antigen
surfac
antigenpres
cell
process
antigen
bind
mhc
molecul
result
cell
surfac
locat
antigenmhc
complex
complex
recogn
tcell
receptor
complex
cell
infect
viru
present
partial
degrad
viral
antigen
ie
endogen
antigen
complex
class
mhc
complex
recogn
cell
result
induct
cytotox
cell
profession
antigenpres
cell
like
macrophag
phagocytos
exogen
antigen
present
conjunct
class
ii
mhc
cell
bind
mhcantigen
complex
subsequ
bcell
macrophag
activ
lead
antibodi
infl
ammatori
respons
respect
classic
vaccin
consist
either
live
attenu
vaccin
nonliv
vaccin
nonliv
vaccin
discern
three
gener
fi
rst
gener
compris
suspens
inactiv
pathogen
organ
secondgener
vaccin
contain
purifi
ed
compon
vari
whole
organ
extract
organ
purifi
ed
singl
compon
thirdgener
vaccin
either
welldefi
ned
mixtur
purifi
ed
compon
protect
compon
formul
immunogen
present
form
exampl
categori
given
tabl
fi
rst
problem
concern
low
immunogen
plain
peptid
vaccin
immunogen
improv
construct
multipl
antigen
peptid
chemic
coupl
peptid
carrier
protein
altern
peptid
epitop
incorpor
carrier
protein
genet
fusion
peptid
dna
carrier
protein
second
problem
peptid
antigen
conform
necessarili
correspond
epitop
nativ
protein
case
bcell
epitop
may
lead
poor
immun
respons
respons
irrelev
peptid
conform
solut
problem
sought
constrain
conform
synthet
peptid
chemic
cycliz
method
advantag
disadvantag
nucleic
acid
vaccin
list
tabl
advantag
rna
risk
incorpor
host
dna
hand
rna
less
stabl
dna
three
product
stage
cultiv
cell
andor
viru
b
purifi
cation
desir
compon
c
formul
vaccin
exampl
combin
vaccin
includ
diphtheriatetanuspertussi
vaccin
measlesmumpsrubella
vaccin
prerequisit
combin
vaccin
compon
pharmaceut
compat
vaccin
compon
addit
b
compat
immun
schedul
c
interfer
immun
respons
individu
compon
